

Electrocardiographic parameters to Detect Cardiac Involvement in Fabry Disease

Original Articles

Yu Wang, MD^{1#}, Jie Kong, Mphil^{1#}, Jun Wang, MD^{2#}, Ru Zhao, MD¹, Heng Wang, MD¹, Jing-Fen Zhu, MD², Bing-Yuan Zhou MD, PhD¹, Cao Zou MD, PhD¹, Ting-Bo Jiang MD, PhD¹, Jia-Li Fan, MD^{1*}, Si-Jia Sun MD, PhD^{1*}

¹Division of Cardiology, Department of Medicine, The First Affiliated Hospital of Soochow University, Suzhou, China.

²Department of Radiology, The First Affiliated Hospital of Soochow University, Suzhou, China.

#These authors have contributed equally to this work.

Short title: ECG Changes in Fabry Disease

Word count:

*Address for Correspondence:

Si-Jia Sun, MD, PhD or Jia-Li Fan, MD

Division of Cardiology, Department of Medicine, The First Affiliated Hospital of Soochow University, No. 188 Shizi Street, Suzhou, China.

E-mail: u3005150@connect.hku.hk or Fanjiali3@163.com

Tel: +86-0512-67781727. Fax: +86-0512-67781727.

Key Words: Electrocardiograph, Cardiomyopathy, Echocardiograph, Fabry Disease

Supplemental Table 1. Reproducibility of ECG analysis.

Variable	ICC (95% CI)
P wave width	0.985 (0.978-0.990)
PR interval	0.974 (0.962-0.983)
Tp-e/QT	0.919 (0.838-0.963)
QTc	0.988 (0.976-0.994)
QRS width	0.957 (0.919-0.980)
II ST depression	0.985 (0.972-0.993)
II negative or biphasic T	0.991 (0.987-0.994)
fQRS	0.996 (0.992-0.998)
Sokolow-Lyon index	0.941 (0.899-0.974)
V5 ST depression	0.993 (0.986-0.997)
V5 negative or biphasic T	0.995 (0.992-0.998)
U wave	0.901 (0.788-0.959)

Supplemental Table 2. Mutations and type of variant in Fabry patients.


Type of Variable	Mutations (variant)
Classical	c.395G>A(p.G132E), c.827G>T(p.S276I), c.298A>T(p.R100X), c.605G>A(p.C202Y), c.708G>A(p.Trp236Ter), c.709A>T(p.Lys237Ter), c.463G>A(p.Asp155Asn), c.695T>G(p.Ile232Ser), c.680G>A(p.Arg227Gln), c.1080-1082delTGG(p.Gly361del), c.748C>A(p.Gln250Lys), c.834T>A(p.Asn278Lys), c.388-390dupAAG(p.lys130dup), c.334C>T(p.Arg112Cys), c.1072-1074delGAG(p.Glu358del), c.1151T>A(p.1384N), c.1046G>A(p.Trp349*), c.898C>T(p.Leu300Phe)
Late onset	c.486G>C(p.Trp162Cys), c.1080-1082delTGG(p.Gly361del), c.658C>T(p.Arg220Ter), c.1087C>T(p.Arg363Cys), c.1066C>T(p.Arg356Trp), c.1013A>G(Glu338Gly), c.1020G>A(p.Trp340*), c.605G>T(p.Cvs202Phechr), c.335G>A(p.Arg122His), c.272T>C(p.191T), c.902G>A(p.Arg301Gln), c.463G>A(p.Asp155Asn), c.644A>G(p.Asn215Ser), c.962A>G(p.Gln321Arg), c.334C>T(p.Arg112Cys), c.898C>T(p.Leu300Phe)

Supplemental Table 3. Correlation between α -galactosidase A and globotriaosylsphingosine with GLS, LVMI, Low T1 and LGE.

Variable	α -galactosidase A		globotriaosylsphingosine	
	R	P	R	P
GLS	0.203	0.166	-0.280	0.069
LVMI	-0.009	0.951	0.254	0.100
Low T1	-0.435	0.004	0.491	0.001
LGE	-0.187	0.236	0.273	0.073

Supplemental Table 4. Linger regression.

	R ²	Durbin-Watson test	B	t	P
Model for GLS	0.671	2.036			
Constant			-26.490	-5.889	<0.001
Gander (Female)			-2.609	-3.093	0.003
Age			0.107	2.523	0.014
Tp-e/QT			-35.818	-2.623	0.011
QRS width			-0.109	4.017	<0.001
Sokolow-Lyon index			0.710	2.845	0.006
Model for LVMI	0.611	1.797			
Constant			27.935	0.499	0.620
Gander (Female)			-36.644	-3.242	0.002
Tp-e/QT			-559.648	-3.225	0.002
QRS width			2.343	6.616	<0.001



Supplemental Figure 1. Schematic illustration of electrocardiographic parameters of interest.